Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
收藏Taylor & Francis Group2022-01-18 更新2026-04-16 收录
下载链接：
https://tandf.figshare.com/articles/dataset/Immune-related_Liver_Injury_is_a_Poor_Prognostic_Factor_in_Patients_with_Nonsmall_Cell_Lung_Cancer_Treated_with_Immune_Checkpoint_Inhibitors/17091839/1
下载链接
链接失效反馈官方服务：
资源简介：
It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; <i>P</i> = 0.010 and <i>P</i> = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.
提供机构：
Ishigami, Masatoshi; Shibata, Hirofumi; Hashimoto, Naozumi; Yamamoto, Kenta; Mizuno, Kazuyuki; Hase, Tetsunari; Honda, Takashi; Abe, Takashi; Ishizu, Yoji; Ito, Takanori; Kawashima, Hiroki; Hatta, Takahiro; Yogo, Naoyuki; Imai, Norihiro; Toyoda, Hidenori; Fujishiro, Mitsuhiro; Yamamoto, Takafumi; Yasuda, Satoshi
创建时间：
2021-11-29
